Back

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?

16 April 2023 (14:30 - 14:38)
Organised by:
Congress Presentation Part of: Atrial Fibrillation - Round 2 - Stroke, ACO Oral Anticoagulation EHRA Premium Access EHRA 2023

About the speaker

Photo
Professor Gregory Yh Lip

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Racial differences in atrial fibrillation-related strokes and mortality.
Doctor K. Dongseon (Anyang-Si- Gyeonggi-Do, KR)
Abstract Slides Video
Presentation thumbnail
Omitting transesophageal echocardiography before catheter ablation of atrial fibrillation or left sided atrial tachycardia in patients on oral anticoagulation.
Mrs V. Maslova (Kiel, DE)
Abstract Slides Video
Presentation thumbnail
Cerebral microembolic signal burden during pulsed field ablation: preliminary results from robotically-assisted transcranial doppler and magnetic resonance imaging
Doctor D. Della Rocca (Brussels, BE)
Abstract Slides Video
Presentation thumbnail
Clinical markers of atrial abnormality as predictors of cardioembolic events in patients with embolic stroke of undetermined source.
Doctor J. Guichard (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
The association of P-terminal force value and increased risk for ischemic stroke among admitted patients in a tertiary hospital: a retrospective case-control study
Doctor M. Manalili Pamplona (San Juan, PH)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial Fibrillation - Round 2 - Stroke, ACO
Video

The Event

Event poster

EHRA 2023

16 April 2023 14:30 CET
You may be interested in
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
thumbnail
Congress Session
Evolution of anticoagulation therapy in patients with atrial fibrillation
thumbnail
Congress Session
Personalised anticoagulation therapy in eligible patients with atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources